Investors Overview

Investors Overview

An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.

Stock Quote

Current value on NASDAQ*

*Stock Price may not reflect real time results

SEC Filings

U.S. Securities and Exchange Commission filings
View SEC Filings

Investor Contact

Will  O’Conner
Stern Investor Relations
will.oconnor@sternir.com

Indaptus Management

View Management Team

Indaptus Board of Directors

View Board of Directors

Press Releases

View Press Releases

Corporate Governance

View Documents and Charters

Events and Presentations

March 28 – 30, 2022

2022 Virtual Growth Conference | Webcast Link

March 14 – 15, 2022

34th Annual ROTH Conference | Webcast Link

January 10, 2022 at 7AM ET

H.C. Wainwright BioConnect 2022 Virtual Conference | Webcast Link

Documents